Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets falls 5.6% from a year ago
Other current assets stood at $268K at the end of Q1 FY2026, down 5.6% from a year earlier and up 257.3% from the prior quarter. Over 3 fiscal years it compounded at -43.3% a year.
Context
- Other current assets amounted to 1.1% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -5.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 75K USD
- Year-over-year change
- +1.4%
- 4-year CAGR
- -4.7%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 75K | +1.4% |
| FY2024 | 2024-12-31 | 74K | +25.4% |
| FY2023 | 2023-12-31 | 59K | -85.7% |
| FY2022 | 2022-12-31 | 412K | +352.7% |
| FY2021 | 2021-12-31 | 91K | — |
Other Current Assets vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 other current assets of $268K is the 9th highest of the 11 companies compared; the peer median is $8.34M.
- Its year-over-year change of -5.6% is the 8th highest of 10, against a peer median of +23.8%.
- Other current assets amounts to 1.1% of total assets for NVCT, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $161.25B | +6889679.5% | +2.1% | 75.1% | |
| Jun 2026 | $13.86M | +67.9% | +44.6% | 1.9% | |
| Mar 2026 | $11.45M | +2027.5% | +118.4% | 2.4% | |
| Mar 2026 | $8.58M | +23.8% | — | 3.8% | |
| Mar 2026 | $8.37M | +4.9% | -4.9% | 3.8% | |
| Mar 2026 | $8.3M | +7.7% | +18.6% | 1.9% | |
| Mar 2026 | $1M | -91.3% | -51.9% | 0.5% | |
| Mar 2026 | $335.74K | +99.4% | +24.5% | 0.4% | |
| Mar 2026 | $268K | -5.6% | -43.3% | 1.1% | |
| Mar 2026 | $73K | -91.4% | -64.8% | 0.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NVCT) | $8.34M | +23.8% | +10.3% | 1.9% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.